Investigator(s):
Christian de Virgilio, MD, FACS
News provided by U.S. Food and Drug Administration
July 7, 2017
The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.
Investigator(s):
Keith Hoffman, PhD
Offers Additional Resources to Help its Startups Succeed
LOS ANGELES – (June 16, 2017) – LA BioMed is launching a Commercialization Accelerator Program™ (CAP), designed and implemented by Larta Institute, that will offer LA BioMed’s early stage bioscience companies additional resources to strengthen and speed their innovations to the marketplace, Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, and Rohit Shukla, Larta Institute CEO, announced today.
Investigator(s):
Jack Edwards Jr., MD
Dr. Edwards Receives the Rhoda Benham Award from Medical Mycology Society
“Congratulations to Dr. Edwards for this important recognition of his many accomplishments and contributions to this field of scientific study,” said David I. Meyer, PhD, LA BioMed president and CEO. “For more than three decades, Dr.
Investigator(s):
The Lundquist Institute
Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities
LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers. Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.
Investigator(s):
The Lundquist Institute
TORRANCE, Calif., May 24, 2017 /PRNewswire/ -- Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of EndariTM for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.
Investigator(s):
The Lundquist Institute
LOS ANGELES – (May 18, 2017) – LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers.
Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.
Investigator(s):
Samuel French, MD
LA BioMed Researcher Honored for Outstanding Work in Liver Disease
The Research Society on Alcoholism (RSA), an organization of researchers who specialize in the study of alcoholism, will honor Samuel W. French, MD, a lead researcher at LA BioMed, with its prestigious 2017 Lifetime Achievement Award for his outstanding work in the field of alcohol research at the organization’s annual scientific meeting in Denver on June 28.
Investigator(s):
The Lundquist Institute
March 9 event features presentations of the latest in breakthrough technologies
On March 9, LA BioMed will host its Fourth Annual Innovation Showcase featuring a full day of break-through technology presentations and speakers that will address issues surrounding the commercialization of technologies.
The showcase at the Manhattan Beach Marriott is expected to attract more than 300 entrepreneurs, investors, executives from biotech and pharma medical devices companies, legal experts, service providers, prominent scientists and technology transfer
Investigator(s):
Christina Chung-Lun Wang, MD
LA BioMed among the institutions that participated in extensive studies of testosterone treatments
Research published today found testosterone treatment improved bone density and anemia for men over 65 with low testosterone. But the treatment didn’t improve patients’ cognitive function, and it increased the amount of plaque buildup in participants’ coronary arteries, according to four studies published in the Journal of the American Medical Association (JAMA) and JAMA Internal Medicine.